Reduction of amyloid-β deposition and attenuation of memory deficits by tolfenamic acid

Journal of Alzheimer's Disease

Volumn 43, Issue 2, 2015, Pages 425-433

  Subaiea, Gehad M ^a   Ahmed, Aseef H ^a   Adwan, Lina I ^a   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

AD transgenic mouse model; Alzheimer's disease; amyloid plaque burden; immunohistochemistry; learning and memory; Morris water maze; tolfenamic acid; Y maze

Indexed keywords

AMYLOID BETA PROTEIN; TOLFENAMIC ACID; AMYLOID PRECURSOR PROTEIN; ANTHRANILIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; SPATIAL LEARNING; TRANSGENIC MOUSE; WORKING MEMORY; Y-MAZE TEST; ANIMAL; C57BL MOUSE; COGNITION DISORDERS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MAZE TEST; MEMORY DISORDERS; METABOLISM; MUTATION; TIME;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; ORTHO-AMINOBENZOATES; TIME FACTORS;

EID: 84911907409     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132726     Document Type: Article

References (53)

1. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, Waters C, Jimison P, Shepherd E, Sevush S, Graff-Radford N, Newland D, Todd M, Miller B, Gold M, Heilman K, Doty L, Goodman I, Robinson B, Pearl G, Dickson D, Duara R (2002) Relative frequencies of Alzheimerdisease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 16, 203-212.
2. Goedert M, Spillantini MG (2006) A century of Alzheimer'sdisease. Science 314, 777-781.
3. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer'sdisease: The challenge of the second century. Sci Transl Med3, 77-71.
4. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U (2010) Amyloid-beta and mitochondria in agingand Alzheimer's disease: Implications for synaptic damageand cognitive decline. J Alzheimers Dis 20(Suppl 2) , S499-S512.
5. Lucin KM, Wyss-Coray T (2009) Immune activation in brainaging and neurodegeneration: Too much or too little? Neuron 64, 110-122.
6. McGeer PL, McGeer EG (1995) The inflammatory responsesystem of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21, 195-218.
7. Urbanc B, Cruz L, Buldyrev SV, Havlin S, Irizarry MC, Stanley HE, Hyman BT (1999) Dynamics of plaque formation inAlzheimer's disease. Biophys J 76, 1330-1334.
8. Golde TE, Cai XD, Shoji M, Younkin SG (1993) Productionof amyloid beta protein from normal amyloid beta-proteinprecursor (beta APP) and the mutated beta APPS linked tofamilial Alzheimer's disease. Ann N Y Acad Sci 695, 103-108.
9. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road totherapeutics. Science 297, 353-356.
10. Ozudogru SN, Lippa CF (2012) Disease modifying drugs targetingbeta-amyloid. Am J Alzheimers Dis Other Demen 27, 296-300.
11. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98, 855-868.
12. Citron BA, Dennis JS, Zeitlin RS, Echeverria V (2008) Transcriptionfactor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res 86, 2499-2504.
13. Santpere G, Nieto M, Puig B, Ferrer I (2006) Abnormal Sp1 transcription factor expression in Alzheimer disease andtauopathies. Neurosci Lett 397, 30-34.
14. Adwan LI, Basha R, Abdelrahim M, Subaiea GM, Zawia NH (2011) Tolfenamic acid interrupts the de novo synthesis of thebeta-amyloid precursor protein and lowers amyloid beta viaa transcriptional pathway. Curr Alzheimer Res 8, 385-392.
15. Subaiea GM, Alansi BH, Serra DA, Alwan M, Zawia NH (2011) The ability of tolfenamic acid to penetrate the brain:A model for testing the brain disposition of candidateAlzheimer's drugs using multiple platforms. Curr Alzheimer Res 8, 860-867.
16. Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH (2013) Short-term treatment with tolfenamic acid improve scognitive functions in Alzheimer's disease mice. Neurobiol Aging 34, 2421-2430.
17. Lehman EJ, Kulnane LS, Lamb BT (2003) Alterations in betaamyloidproduction and deposition in brain regions of twotransgenic models. Neurobiol Aging 24, 645-653.
18. Kulnane LS, Lamb BT (2001) Neuropathological characterizationof mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 8, 982-992.
19. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW (1996) Enhanced amyloidogenicprocessing of the beta-amyloid precursor protein ingene-targeted mice bearing the Swedish familial Alzheimer'sdisease mutations and a "humanized" Abeta sequence. J Biol Chem 271, 23380-23388.
20. Hock BJ, Jr. , Lamb BT (2001) Transgenic mouse models of Alzheimer's disease. Trends Genet 17, S7-S12.
21. Lamb BT, Call LM, Slunt HH, Bardel KA, Lawler AM, Eckman CB, Younkin SG, Holtz G, Wagner SL, Price DL, Sisodia SS, Gearhart JD (1997) Altered metabolism of familial Alzheimer's disease-linked amyloid precursor proteinvariants in yeast artificial chromosome transgenic mice. Hum Mol Genet 6, 1535-1541.
22. Lamb BT, Bardel KA, Kulnane LS, Anderson JJ, Holtz G, Wagner SL, Sisodia SS, Hoeger EJ (1999) Amyloid productionand deposition in mutant amyloid precursor protein andpresenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci 2, 695-697.
23. Hock BJ, Lattal KM, Kulnane LS, Abel T, Lamb BT (2009) Pathology associated memory deficits in Swedish mutantgenome-based amyloid precursor protein transgenic mice. Curr Aging Sci 2, 205-213.
24. Lillehaug S, Syverstad GH, Nilsson LN, Bjaalie JG, Leergaard TB, Torp R (2014) Brainwide distribution and varianceof amyloid-beta deposits in tg-ArcSwe mice. Neurobiol Aging35, 556-564.
25. Wadghiri YZ, Li J, Wang J, Hoang DM, Sun Y, Xu H, Tsui W, Li Y, Boutajangout A, Wang A, de Leon M, Wisniewski T (2013) Detection of amyloid plaques targeted by bifunctionalUSPIO in Alzheimer's disease transgenic mice usingmagnetic resonance microimaging. PLoS One 8, e57097.
26. Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN (2006) Abeta42 gene vaccination reduces brain amyloidplaque burden in transgenic mice. J Neurol Sci 244, 151-158.
27. Vorhees CV, Williams MT (2006) Morris water maze: Proceduresfor assessing spatial and related forms of learning andmemory. Nat Protoc 1, 848-858.
28. Laczo J, Vlcek K, Vyhnalek M, Vajnerova O, Ort M, Holmerova I, Tolar M, Andel R, Bojar M, Hort J (2009) Spatialnavigation testing discriminates two types of amnesticmild cognitive impairment. Behav Brain Res 202, 252-259.
29. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, Choi CH, McBride SM, Faber DS (2009) Validationof a 2-day water maze protocol in mice. Behav Brain Res 196, 220-227.
30. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ (1999) Progressive and gender-dependent cognitiveimpairment in the APP (SW) transgenic mouse model forAlzheimer's disease. Behav Brain Res 103, 145-162.
31. Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, Goodison S, Adwan L, Zawia NH, Lichtenberger LM, Basha R (2013) Cellular and organismal toxicity of theanti-cancer small molecule, tolfenamic acid: A pre-clinicalevaluation. Cell Physiol Biochem 32, 675-686.
32. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subsetof NSAIDs lower amyloidogenic Abeta42 independently ofcyclooxygenase activity. Nature 414, 212-216.
33. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, Paul SM, NiB (2003) Nonsteroidal anti-inflammatory drugs can loweramyloidogenic Abeta42 by inhibiting Rho. Science 302, 1215-1217.
34. Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, Hyman BT (2004) Nonsteroidal antiinflammatorydrugs lower Abeta42 and change presenilin 1conformation. Nat Med 10, 1065-1066.
35. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC (2001) BACE1 is the major beta-secretase forgeneration of Abeta peptides by neurons. Nat Neurosci 4, 233-234.
36. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W (2004) Transcriptional regulation of BACE1, thebeta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 24, 865-874.
37. Sambamurti K, Kinsey R, Maloney B, Ge YW, Lahiri DK (2004) Gene structure and organization of the human betasecretase (BACE) promoter. FASEB J 18, 1034-1036.
38. Lahiri DK, Robakis NK (1991) The promoter activity ofthe gene encoding Alzheimer beta-amyloid precursor protein (APP) is regulated by two blocks of upstream sequences. Brain Res Mol Brain Res 9, 253-257.
39. Wilkinson BL, Cramer PE, Varvel NH, Reed-Geaghan E, Jiang Q, Szabo A, Herrup K, Lamb BT, Landreth GE (2012) Ibuprofen attenuates oxidative damage through NOX2 inhibitionin Alzheimer's disease. Neurobiol Aging 33, 197e121-132.
40. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mousemodel for Alzheimer's disease. J Neurosci 20, 5709-5714.
41. Zawia NH, Basha MR (2005) Environmental risk factors andthe developmental basis for Alzheimer's disease. Rev Neurosci 16, 325-337.
42. Adwan L, Zawia NH (2013) Epigenetics: A novel therapeuticapproach for the treatment of Alzheimer's disease. Pharmacol Ther 139, 41-50.
43. Lahiri DK, Maloney B, ZawiaNH (2009) The LEARn model:An epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14, 992-1003.
44. Zawia NH, Lahiri DK, Cardozo-Pelaez F (2009) Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med46, 1241-1249.
45. Molfese DL (2011) Advancing neuroscience through epigenetics:Molecular mechanisms of learning and memory. DevNeuropsychol 36, 810-827.
46. Sultan FA, Day JJ (2011) Epigenetic mechanisms in memoryand synaptic function. Epigenomics 3, 157-181.
47. Liu L, van Groen T, Kadish I, Tollefsbol TO (2009) DNAmethylation impacts on learning and memory in aging. Neurobiol Aging 30, 549-560.
48. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyl transferasesDnmt3a and Dnmt3b are essential for de novomethylation and mammalian development. Cell 99, 247-257.
49. Lalonde R (2002) The neurobiological basis of spontaneousalternation. Neurosci Biobehav Rev 26, 91-104.
50. Van Dam D, Coen K, De Deyn PP (2008) Cognitive evaluationof disease-modifying efficacy of donepezil in the APP23mouse model for Alzheimer's disease. Psychopharmacology (Berl) 197, 37-43.
51. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM (2010) Memantine improves cognition andreduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176, 870-880.
52. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces Abeta, hyperphosphorylated tau and memorydeficits in Alzheimer mice. Brain Res 1207, 225-236.
53. Herrmann N, Chau SA, Kircanski I, Lanctot KL (2011) Currentand emerging drug treatment options for Alzheimer'sdisease: A systematic review. Drugs 71, 2031-2065.